Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market was valued at USD 0.15 Billion in 2022 and is projected to reach USD 0.3 Billion by 2030, growing at a CAGR of 9.2% from 2024 to 2030.
The Japan VPM1002 market, which involves the tuberculosis BCG-based vaccine, is segmented into various applications catering to different segments of the population. This vaccine, derived from the BCG (Bacillus Calmette-Guérin) strain, is utilized primarily for the prevention of tuberculosis (TB), a serious infectious disease that primarily affects the lungs. The key applications of VPM1002 in Japan encompass several areas, including the prevention of TB in high-risk groups, general population vaccination, and use in specific clinical settings. Each segment has unique characteristics and requirements, influencing the demand for VPM1002 across the country.
In high-risk groups, such as individuals with close contact to TB patients or those with weakened immune systems, the VPM1002 vaccine plays a crucial role in preventing the onset of tuberculosis. This application is vital in controlling the spread of TB within communities where the disease is prevalent or among populations more susceptible to infection. The general population vaccination segment aims to provide broad coverage and immunity against tuberculosis, thereby contributing to the overall public health strategy in Japan. Additionally, VPM1002 is used in clinical settings for specific indications, such as the prevention of TB in patients undergoing certain treatments or those with occupational exposure risks.
Get an In-Depth Research Analysis of the Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market Size And Forecast [2025-2032]
Vakzine Projekt Management (VPM)
Serum Institute of India
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
Based on Types the Market is categorized into Below types that held the largest VPM1002 (Tuberculosis BCG Based Vaccine) market share In 2023.
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
Japan (United States, Japan and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ VPM1002 (Tuberculosis BCG Based Vaccine) Market Research Analysis
1. Introduction of the Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market, By Type
6. Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market, By Application
7. Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market, By Geography
Japan
Europe
Asia Pacific
Rest of the World
8. Japan VPM1002 (Tuberculosis BCG Based Vaccine) Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Japan Research and Consulting firm servicing over 5000+ Japan clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/